TRIM67通过Rho GTP酶依赖性膜泡驱动少突胶质细胞瘤肿瘤发生
本研究识别出E3泛素连接酶TRIM67在少突胶质细胞瘤中特异性上调并作为癌基因。体外实验显示TRIM67过表达改变细胞骨架蛋白丰度、诱导膜泡形成,该过程可被blebbistatin和fasudil逆转,并与NOGO-A/Rho GTP酶/ROCK2信号改变相关;原位植入患者来源少突胶质细胞瘤肿瘤球后,TRIM67加速肿瘤生长、降低总生存并增加肿瘤边缘波形蛋白表达。
要点
- TRIM67在少突胶质细胞瘤中特异性上调并发挥癌基因作用。
- TRIM67过表达通过Rho GTP酶/ROCK信号诱导膜泡和圆形细胞形态。
- 原位植入模型中TRIM67加速肿瘤生长并降低总生存。
核心结论
- 上调的TRIM67通过Rho GTP酶/ROCK介导的信号诱导基于膜泡的圆形细胞形态,从而促进胶质瘤发病机制。
研究设计与样本
- 使用多种细胞系(包括患者来源少突胶质细胞瘤肿瘤球)敲低或过表达TRIM67。
- 结合高通量检测(RNA测序、总裂解物质谱、免疫共沉淀-质谱)与功能检测(免疫荧光染色、免疫共沉淀、蛋白质印迹)评估体外表型。
- 将患者来源少突胶质细胞瘤肿瘤球原位植入小鼠以确定TRIM67对肿瘤生长和生存的影响。
主要发现
- TRIM67过表达改变细胞骨架蛋白丰度并诱导膜泡形成。
- TRIM67相关膜泡可被非肌肉II类肌球蛋白抑制剂blebbistatin和选择性ROCK抑制剂fasudil逆转。
- TRIM67异位表达时NOGO-A/Rho GTP酶/ROCK2信号发生改变。
- TRIM67表达导致更高的细胞运动性和降低的细胞黏附。
- 在患者来源少突胶质细胞瘤原位植入模型中,TRIM67加速肿瘤生长、降低总生存并导致肿瘤边缘波形蛋白表达增加。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: IDH mutant gliomas are grouped into astrocytomas or oligodendrogliomas depending on the codeletion of chromosome arms 1p and 19q. Although the genomic alterations of IDH mutant gliomas have been well described, transcriptional changes unique to either tumor type have not been fully understood. Here, we identify Tripartite Motif Containing 67 (TRIM67), an E3 ubiquitin ligase with essential roles during neuronal development, as an oncogene distinctly upregulated in oligodendrogliomas. METHODS: We used several cell lines, including patient-derived oligodendroglioma tumorspheres, to knock down or overexpress TRIM67. We coupled high-throughput assays, including RNA sequencing, total lysate-mass spectrometry (MS), and coimmunoprecipitation (co-IP)-MS with functional assays including immunofluorescence (IF) staining, co-IP, and western blotting (WB) to assess the in vitro phenotype associated with TRIM67. Patient-derived oligodendroglioma tumorspheres were orthotopically implanted in mice to determine the effect of TRIM67 on tumor growth and survival. RESULTS: TRIM67 overexpression alters the abundance of cytoskeletal proteins and induces membrane bleb formation. TRIM67-associated blebbing was reverted with the nonmuscle class II myosin inhibitor blebbistatin and selective ROCK inhibitor fasudil. NOGO-A/Rho GTPase/ROCK2 signaling is altered upon TRIM67 ectopic expression, pointing to the underlying mechanism for TRIM67-induced blebbing. Phenotypically, TRIM67 expression resulted in higher cell motility and reduced cell adherence. In orthotopic implantation models of patient-derived oligodendrogliomas, TRIM67 accelerated tumor growth, reduced overall survival, and led to increased vimentin expression at the tumor margin. CONCLUSIONS: Taken together, our results demonstrate that upregulated TRIM67 induces blebbing-based rounded cell morphology through Rho GTPase/ROCK-mediated signaling thereby contributing to glioma pathogenesis.
引用
- Demirdizen E, Al-Ali R, Narayanan A, et al. TRIM67 drives tumorigenesis in oligodendrogliomas through Rho GTPase-dependent membrane blebbing. Neuro Oncol. 2023. PMID: 36215168. doi:10.1093/neuonc/noac233
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。